Updated on 18.03.2025.
The European healthtech sector has been steadily growing in recent years. Even though economic constraints, changing policies and regulations around healthcare have impacted its rise, 2024 saw a dynamic interplay between innovation and capital availability. With digital health investments reaching $3.5 billion — a 19% year-over-year increase — key European markets saw remarkable investor interest, driven in part by transformative AI-led advancements in diagnostics, personalized medicine, and pharma tech.
Vestbee has updated its list of top healthtech VC funds investing in Europe, showcasing the key players driving innovation in the healthcare, biotech, and medtech industries. This collection details their investment focus and typical ticket sizes. By analyzing investment data from DaaS platforms such as Crunchbase and Dealroom, we’ve identified funds that led the way in 2024 and continue investing actively worldwide in 2025.
Here is a comprehensive list of the top healthtech VC funds investing in Europe:
Ananda Impact Ventures
HQ: Munich, Germany
Sector: impact-driven ventures in health, climate, sustainability, and social innovation
Stage: seed to Series A
Ananda Impact Ventures backs mission-driven entrepreneurs building companies that combine financial success with meaningful social and environmental impact. With a geographic focus on DACH, UK, Benelux, and Scandinavia, Ananda invests in early-stage for-profit enterprises with global growth potential. Its €108 million fund supports startups tackling sustainability, healthtech, and deep social challenges, with portfolio companies spanning biodiversity, AI-driven healthcare, and climate resilience
APEX Ventures
HQ: Vienna, Austria
Sector: deeptech, medtech, AI, and intellectual property-driven innovations
Stage: early stages
APEX Ventures is an early-stage venture capital firm specializing in deep tech and medical technologies with defensible intellectual property at its core. They invest in scientific breakthroughs and engineering innovations that can scale across multiple industries. With a geographic focus on DACH, CEE, Nordics, and the US, APEX Ventures provides initial investments ranging from €500,000 to €1.5 million, supporting startups through validation, scalability, and growth stages.
Calm/Storm
HQ: Vienna, Austria
Sector: digital health, femtech, mental health, sexual wellness, chronic care
Stage: pre-seed, seed
Calm/Storm Ventures backs purpose-driven founders tackling digital health and wellbeing challenges, particularly in taboo-breaking sectors such as fertility, sexual wellness, mental health, and chronic conditions. The fund invests at the super-early stage, often before a finalized co-founding team or pitch deck, providing hands-on support and a strong founder community. The firm has a strong commitment to diversity, with nearly 50% of portfolio companies featuring diverse teams and 30% of CEOs identifying as non-male.
Eight Roads
HQ: London, UK
Sector: technology & healthcare
Stage: early to growth stages
Eight Roads Ventures is a global investment firm with over 50 years of experience, managing more than $11 billion in assets and supporting over 500 portfolio companies worldwide. The firm operates across multiple regions, including Asia, Europe, Israel, and the US, with dedicated teams there. It focuses on partnering with ambitious technology and healthcare companies. Eight Roads’ investment sectors encompass consumer, enterprise, fintech, healthcare IT, healthcare services, medtech, and pharma & therapeutics.
HQ: Brussels, Belgium
Sector: healthtech, medtech, biotech, Digital Health
Stage: late seed, Series A, growth
EIT Health is a pan-European network supporting healthtech startups through funding, mentorship, and acceleration programs. It focuses on strengthening healthcare systems, digital transformation, and health innovation by connecting startups with key players in research, business, and education. EIT Health facilitates access to the EIC Accelerator, providing up to €2.5 million in grants and €15 million in equity investments. It also offers targeted programs such as Gold Track, Bridgehead, and Bootcamps to help startups expand into new markets, scale operations, and attract private investment.
Elaia Partners
HQ: Paris, France
Sector: digital tech, deeptech, B2B tech, healthtech
Stage: pre-seed, seed, Series A, Series B
Elaia VC's investment thesis spans from pre-seed to Series B, with ticket sizes ranging from €300,000 to €15 million per company. The firm targets high-potential B2B startups in the digital, deep tech, and biotech sectors, primarily within Europe and Israel. With a global outlook, the firm nurtures local innovation while fostering the ambitions of visionary founders.
Entrepreneur First
HQ: London, UK
Sector: AI, deeptech, healthtech (excluding drugs and vaccines)
Stage: pre-seed, seed
EF is a talent-focused venture fund that invests in individuals before they have a company, helping them form teams and build globally significant startups. EF’s investment focus spans AI and machine learning, enterprise software, robotics, cybersecurity, fintech, healthtech (excluding drug development), and Web3 infrastructure. The fund provides an equity-free grant for founders to focus on company formation, followed by potential investment of up to $250,000. EF has a structured 24-week program across Europe, the US, and Asia, guiding founders through ideation, co-founder matching, and fundraising preparation.
EQT Life Sciences
HQ: Stockholm, Sweden
Sector: biotech, medtech, healthtech, diagnostics
Stage: early, late, and growth stages
EQT Life Sciences is one of Europe’s largest and most experienced life sciences investors, managing €3.5 billion across 12 funds. The firm invests between €10-60 million per company, targeting biotech, medtech, digital health, and diagnostics. It actively supports startups with strategic, clinical, and operational guidance. Key funds include LSP Biotech Funds, Health Economic Funds, and the Dementia Fund, which focus on transformative medical breakthroughs.
F-Prime Capital
HQ: London, UK
Sector: healthcare (therapeutics, medtech, health IT & services)
Stage: early to growth stages
F-Prime Capital is a global venture capital firm investing in healthcare and technology companies that improve lives worldwide. With over $4.5 billion in assets under management and a portfolio of over 370 companies, including over 30 startups built from scratch, F-Prime provides deep industry expertise and capital at scale. The firm invests across the Americas, Europe, and Asia, backing therapeutics, medtech, and digital health innovations.
Forbion Capital Partners
HQ: Naarden, Netherlands
Sector: biotech, life sciences, Medtech, bioeconomy
Stage: seed, Series A, growth
Forbion has a focus on biotech, medtech, and bioeconomy innovations. The firm invests at all stages, from company formation (BioGeneration Ventures) and early-stage funding (Forbion Ventures) to late-stage growth (Forbion Growth Opportunities Fund). The firm focuses on scientific areas with high unmet medical need, including autoimmune diseases, cardiovascular and metabolic disorders, central nervous system diseases, digestive and renal conditions, and oncology. Backed by the EIF and major institutional investors, Forbion provides capital, operational expertise, and strategic guidance to help companies scale.
High-Tech Gründerfonds
HQ: Bonn, Germany
Sector: life sciences, biotech, digital tech, industrial & deeptech
Stage: pre-seed and seed
HTGF is Germany’s leading early-stage investor, backing tech-driven startups from pre-seed to seed. With initial investments starting at more than €800,000 and follow-on funding up to €30 million, the fund provides capital, expertise, and access to an extensive network of co-investors.
Hoxton Ventures
HQ: London, UK
Sector: generalist
Stage: pre-seed, seed
Hoxton Ventures is a London-based VC firm with a Silicon Valley mindset, backing early-stage European startups aiming for global market leadership. The firm is deliberately anti-thematic, focusing on new category creation and technical founders with bold visions. It typically invests $500,000-5 million, leading or co-leading pre-seed and seed rounds while reserving capital for follow-ons. Hoxton strongly encourages startups to enter the US market early, leveraging its Silicon Valley network to open doors and accelerate growth.
Index Ventures
HQ: London, UK
Sector: generalist
Stage: from early to growth stages
Index Ventures, headquartered in London, San Francisco, and Geneva, spans more than 1000 investments in companies like Adyen, Deliveroo, and Dropbox. Offering strategic guidance and global connections, Index Ventures supports innovation across software, e-commerce, fintech, health tech and more. It is investing from the earliest and seed stages up to the late stages, working with entrepreneurs and their companies at every stage, across every sector.
Inkef VC
HQ: Amsterdam, Netherlands
Sector: healthcare (therapeutics, digital health, medical devices), technology (future of commerce, future of work, data & AI, software engineering, fintech, deeptech)
Stage: seed, Series A
Inkef is an early-stage, hands-on investor focused on long-term value creation. With a strong sector focus on healthcare and technology, Inkef partners with mission-driven entrepreneurs to support breakthrough innovations in globally relevant markets. The fund prioritizes patient capital, investing in teams that demonstrate ambition, technical depth, and scalability potential. Typical investments range from seed to Series A, with the flexibility to go earlier or later for exceptional opportunities.
Karista VC
HQ: Paris, France
Sector: health, digital tech, new space
Stage: seed, Series A, Series B
Karista is an early and growth-stage VC fund backing innovative startups across Western Europe in healthcare, biotech, medtech, and digital health. With initial investments ranging from €500,000 to €5 million and follow-on commitments up to €10 million, the fund actively supports startups that leverage data to enhance patient care, optimize clinical workflows, or transform the patient journey. Karista often leads investment rounds and takes board seats to provide strategic guidance.
Kurma Partners
HQ: Paris, France
Sector: biotech, medtech, diagnostics, therapeutics
Stage: early stages
Kurma Partners is a healthcare-focused VC with €870 million under management, specializing in company creation and early-stage investments in biotech, medtech, and diagnostics. The firm has founded startups by collaborating closely with leading research institutions to turn disruptive scientific discoveries into commercial solutions. It operates multiple funds, including Kurma Biofunds (I-IV) for early-stage biotech, Kurma Diagnostics for medtech, and Kurma Growth Opportunities for later-stage investments.
Mercia Ventures
HQ: London, UK
Sector: generalist (including healthtech, biotech, medtech, deeptech, SaaS, AI, and more)
Stage: seed, Series A, growth
Mercia Ventures provides capital and support to startups across a broad range of sectors. The firm primarily focuses on UK-based companies, particularly those outside of London and the South East, addressing the funding gap in regional markets. It actively co-invests with other top-tier funds and provides extensive post-investment support through Mercia Nucleus, which includes talent acquisition, sector expertise, and strategic growth guidance. The firm manages multiple regional and national funds.
Nina Capital
HQ: Barcelona, Spain
Sector: healthtech, digital health, AI in healthcare, data & compute technologies
Stage: pre-seed, seed, Series A
Nina Capital invests at the intersection of healthcare and technology, backing need-driven founders applying data, computing, and digital technologies to transform healthcare. The firm follows the Biodesign methodology, prioritizing startups that solve critical healthcare challenges through deep technology and data-driven solutions. Nina Capital invests across Europe, the US, Canada, Israel, and Australia, with ticket sizes ranging from €200,000 to €1.5 million, and can lead or co-invest in funding rounds. The fund does not invest in drugs or vaccines, focusing instead on software, digital infrastructure, and AI-driven solutions that improve patient outcomes and healthcare efficiency.
NLC Health Ventures
HQ: Amsterdam, Netherlands
Sector: healthtech, biotech, medtech, digital health
Stage: pre-seed, seed, early-stage
NLC Health Ventures is Europe’s leading healthtech venture builder and early-stage investor, dedicated to bridging the gap between scientific discoveries and market-ready healthcare solutions. The firm builds and scales over 25 ventures per year across biotech, cardiovascular, orthopedics & spine, and general healthtech, bringing innovations in prevention, diagnosis, treatment, and self-care to market.
Novartis Venture Fund
HQ: Basel, Switzerland
Sector: biotechnology, biopharmaceuticals
Stage: seed, early and growth stages
Novartis Venture Fund invests in biotechnology and biopharmaceutical companies that are developing innovative therapeutics and drug platforms aimed at addressing serious and currently untreated or poorly managed diseases. This means the fund seeks startups working on treatments for conditions with limited or no effective medical solutions, such as rare diseases, oncology, neurology, immunology, and other critical therapeutic areas. NVF’s portfolio spans North America and Europe, funding both early-stage startups and later-phase ventures.
Novo Holdings
HQ: Hellerup, Denmark
Sector: life sciences, biotech, medtech, healthcare services, industrial biosolutions
Stage: seed, growth, late stages
Novo Holdings is one of the world's largest life science investors, managing €149 billion in assets on behalf of the Novo Nordisk Foundation. The firm invests across the full lifecycle of healthcare and biotech startups, from seed-stage companies to publicly traded firms, with a strong emphasis on long-term strategic support. It deploys capital through Venture, Growth, and Principal Investments, with ticket sizes varying based on stage and need.
Octopus Ventures
HQ: London, UK
Sector: B2B software, bio, climate, consumer, deeptech, fintech, health
Stage: pre-seed, seed, Series A, growth
Octopus Ventures backs founders tackling global challenges with scalable, high-impact solutions. With a sector-focused approach, it invests from pre-seed to Series A and beyond, with initial ticket sizes ranging from £100,000 to £10 million. As a certified B Corp, the firm prioritizes purpose-driven businesses, particularly in healthtech, climate innovation, and frontier technology.
Panakes Partners
HQ: Milan, Italy
Sector: biotech, medtech, digital health
Stage: seed, Series A, growth
Panakes Partners invests in early-stage life sciences startups that address high unmet medical needs. The fund primarily backs biotech, medtech, and digital health companies across Europe and Israel, supporting them with both capital and strategic guidance. Initial investments range from €500,000 to €1.5 million, with follow-on funding available for scaling. The firm has backed notable startups in oncology, cardiovascular, neuromodulation, and regenerative medicine.
Prima Materia
HQ: Stockholm, Sweden
Sector: healthech, clean energy, AI, natural resources
Stage: early stages
Prima Materia is a European investment and company-building initiative, focused on developing transformative technologies with long-term societal impact. Unlike traditional venture capital firms, it actively co-creates companies alongside founders, prioritizing early-stage investments in moonshot projects across healthcare, AI, clean energy, and natural resources. The firm operates with a hands-on approach, offering deep industry expertise, strategic guidance, and capital to a small, highly selective portfolio.
Redalpine
HQ: Zurich, Switzerland
Sector: deeptech, healthtech, biotech, fintech, sustainability
Stage: pre-seed, seed, Series A, growth
Redalpine is a pan-European, multi-stage VC investing at the intersection of software and science. Since 2006, the firm has backed high-impact startups that are redefining healthcare, frontier tech, fintech, digitization, and sustainability. With a team composed of scientists, doctors, and operators, Redalpine provides deep sector expertise and hands-on operational support beyond capital. The fund typically leads rounds with initial tickets from €500,000 to €5 million and follow-on funding for scale.
Seedcamp
HQ: London, UK
Sector: generalist
Stage: early stages
Seedcamp is an early-stage, mostly seed, venture capital firm that backs startups attacking large, global markets and solving real problems using technology. It is based in London but invests globally, across a variety of sectors and solutions, including but not limited to software, hardware, marketplaces, fintech, healthtech, and AI/ML. The fund has a broad network of investors, mentors, and experts who provide support and guidance to their portfolio companies. As a first-cheque investor, Seedcamp is typically investing between $350,000 to $1 million in founders, at any stage of product development.
Seventure
HQ: Paris, France
Sector: life sciences (microbiome, nutrition, foodtech, biotech, medtech, digital health, industrial biotech, animal health) & digital technologies (fintech, retail tech, insurtech, AI, software)
Stage: early to late stages
Seventure Partners is a leading European venture capital firm specializing in life sciences and digital technologies, with a strong reputation in microbiome research investments. It provides capital from seed to growth stage, with a hands-on approach in guiding startups toward commercialization. The firm’s Health for Life Capital fund is globally recognized for its pioneering investments in microbiome, nutrition, and personalized medicine. Seventure also backs medtech, biotech, and industrial biotech innovations, particularly in Europe and North America.
SFC Capital
HQ: London, UK
Sector: healthtech, medtech, fintech, B2B software, green tech
Stage: pre-seed, seed
SFC Capital is the UK’s leading SEIS and EIS fund, specializing in early-stage investments across healthtech and other high-growth sectors. It backs 15-20 companies per SEIS fund and 10-15 per EIS fund, leveraging partnerships with Innovate UK and the British Business Bank to support promising startups. With over 400 portfolio companies and iver £150 million in AUM, SFC provides both direct angel investments and structured SEIS/EIS tax-advantaged funds.
Sofinnova Partners
HQ: Paris, France
Sector: biotech, medtech, healthtech, industrial biotech
Stage: early and growth stages
Sofinnova Partners is a leading European life sciences VC with over €4 billion in AUM, investing in biotech, medtech, and healthtech startups that drive breakthrough innovation. With a 50-year track record and over 500 companies backed, the firm provides early to late-stage funding, helping startups scale globally. Its portfolio includes market-leading biotech and medtech firms, and it actively supports entrepreneurs in company building, product development, and commercialization.
SV Health Investors
HQ: London, UK
Sector: biotech, medtech, healthcare growth, dementia therapeutics
Stage: from early to late and growth stages
SV Health Investors is a specialist healthcare fund manager with $3.7 billion in commitments and over 30 years of experience investing across biotech, medtech, and healthcare services. The firm operates strategy-specific funds, including the SV Biotech Fund, the Growth Fund for healthcare services and digital health, and the Medtech Convergence Fund. Additionally, it manages the Dementia Discovery Fund, which backs novel therapeutics targeting neurodegenerative diseases.
Thuja Capital
HQ: Utrecht, Netherlands
Sector: biotech, medtech, nutraceuticals, digital health
Stage: from early to late stages
Thuja Capital is a healthcare-focused venture capital firm investing in innovative biotech, medtech, digital health, and nutraceutical companies with clinically validated, defensible products and global market potential. The firm takes a structured, risk-balanced approach, providing investments that support sustainable growth. Rooted in the Benelux region but operating across Europe, Thuja actively partners with founders, offering strategic guidance, operational expertise, and access to an extensive industry network.
Verve Ventures
HQ: Zurich, Switzerland
Sector: deeptech, health & bio, future of computing, energy & resources
Stage: from seed to growth
Verve Ventures is a leading European deeptech investor, backing science and technology startups with high-impact innovations in health, computing, and sustainability. With annual investments of €60-70 million, the fund is among Europe’s most active VCs, co-investing alongside top-tier funds in competitive rounds. Verve has invested in over 150 startups across Europe, including healthtech ventures focusing on areas such as biotech or AI-driven solutions in the healthcare space.
Vinci S.A.
HQ: Warsaw, Poland
Sector: biotechnology, space industry, renewable energy, IT, innovative industries
Stage: from early to growth stages
Vinci S.A. is a Polish investment firm managing three key alternative investment funds: HiTech ASI backs high-tech startups and scaleups with investments of up to PLN 40 million, focusing on commercialization and expansion. IQ ASI serves as an incubator fund, investing up to PLN 90 million in early-stage scientific research and patentable technologies with strong commercial potential. Da Gama ASI facilitates the international expansion of Polish enterprises, offering PLN 10-90 million in equity, debt, or mezzanine financing.
Ysios Capital
HQ: San Sebastian & Barcelona, Spain
Sector: biotechnology (therapeutic drugs)
Stage: early to late stages
Ysios Capital is a leading European venture capital firm specializing in biotech investments, with a strong focus on developing innovative therapeutic drugs that address high unmet medical needs. With over €400 million in assets under management, Ysios Capital has backed 18 portfolio companies, bringing 15 products to market and supporting more than 42 clinical-stage treatments. The firm operates globally, seeking exceptional teams and groundbreaking science to drive medical breakthroughs that transform patient care.
YZR Capital
HQ: Munich, Germany
Sector: healthtech
Stage: pre-seed, seed, Series A, growth
YZR is a sector-focused venture capital firm dedicated to backing Europe’s most disruptive healthtech startups. With deep expertise in healthcare and regulatory frameworks, YZR provides capital, strategic guidance, and operational resources to help founders navigate early-stage challenges and scale into European market leaders. The firm invests from (pre)-seed to Series A and selectively in growth-stage companies, focusing on efficiency, transparency, and systemic innovation in healthcare.
